[HTML][HTML] Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on …
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - Medrxiv, 2022 - medrxiv.org
ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe …
Real-world effectiveness of nirmatrelvir/ritonavir in preventing hospitalization among patients with COVID-19 at high risk for severe disease in the United States: a …
X Zhou, SP Kelly, C Liang, L Li, R Shen… - medRxiv, 2022 - medrxiv.org
Objectives The aim of this analysis was to describe nirmatrelvir/ritonavir real-world
effectiveness in preventing hospitalization among high-risk US COVID-19 patients during …
effectiveness in preventing hospitalization among high-risk US COVID-19 patients during …
Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada
Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …
[HTML][HTML] Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk …
Background Timely evidence of the comparative effectiveness between COVID-19 therapies
in real-world settings is needed to inform clinical care. This study aimed to compare the …
in real-world settings is needed to inform clinical care. This study aimed to compare the …
[HTML][HTML] Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
Objective To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
vaccinated and unvaccinated non-hospitalized adults with COVID-19. Methods …
Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during …
LE Wee, AT Tay, C Chiew, BE Young, B Wong… - Clinical Microbiology …, 2023 - Elsevier
Objectives Real-world data on continued effectiveness of nirmatrelvir/ritonavir against
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
hospitalization and severe COVID-19 in the context of widespread booster mRNA vaccine …
[HTML][HTML] Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …
Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections
Importance Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …
in other countries to treat nonhospitalized patients who have mild-to-moderate COVID-19 …